Novel Therapies for Eosinophilic Disorders

Immunology and Allergy Clinics of North America

Volumn 35, Issue 3, 2015, Pages 577-598

  Bochner, Bruce S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antibodies; Biomarkers; Eosinophil; Pharmacology; Targets; Therapies

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ALTRAKINCEPT; AMG 157; ANRUKINZUMAB; ANTISENSE OLIGONUCLEOTIDE; BENRALIZUMAB; BIOLOGICAL PRODUCT; DACLIZUMAB; ETROLIZUMAB; GEMTUZUMAB; GLUCOCORTICOID; GW 766944; HYDROXYUREA; IMATINIB; LEBRIKIZUMAB; LIPOSOME; MEPOLIZUMAB; MONTELUKAST; NANOPARTICLE; NATALIZUMAB; PASCOLIZUMAB; PITRAKINRA; PROTEIN TYROSINE KINASE INHIBITOR; RESLIZUMAB; STEROID; TRALOKINUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOLIZUMAB; ZILEUTON; CELL SURFACE RECEPTOR; CYTOKINE; MONOCLONAL ANTIBODY;

ALLERGIC RHINITIS; ASTHMA; CELL STRUCTURE; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC DISORDER; EOSINOPHILIC ESOPHAGITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW; TOXICITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ASTHMA; CYTOKINES; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MOLECULAR TARGETED THERAPY; RECEPTORS, CELL SURFACE;

EID: 84937692015     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.05.007     Document Type: Review

References (133)

1. Bochner B.S., Book W., Busse W.W., et al. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol 2012, 130:587-596.
2. Boucher R.M., Gilbert-McClain L., Chowdhury B. Hypereosinophilic syndrome and mepolizumab. N Engl J Med 2008, 358:2838-2839. [author reply: 2839-40].
3. Radonjic-Hoesli S., Valent P., Klion A.D., et al. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol 2015, 55:633-656.
4. Fulkerson P.C., Rothenberg M.E. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013, 12:117-129.
5. Iwasaki H., Mizuno S., Mayfield R., et al. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005, 201:1891-1897.
6. Gauvreau G.M., Ellis A.K., Denburg J.A. Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009, 39:1297-1306.
7. Ackerman S.J., Bochner B.S. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007, 27:357-375.
8. Rothenberg M.E., Hogan S.P. The eosinophil. Annu Rev Immunol 2006, 24:147-174.
9. Kita H., Bochner B.S. Biology of eosinophils. Middleton's allergy principles and practice 2014, 265-279. Elsevier Sanders, Philadelphia. 8th edition. N.F. Adkinson, B.S. Bochner, W.W. Busse (Eds.).
10. Eosinophils in health and disease 2012, Elsevier, Amsterdam. J.J. Lee, H.F. Rosenberg (Eds.).
11. Rosenberg H.F., Dyer K.D., Foster P.S. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013, 13:9-22.
12. von Gunten S., Ghanim V., Valent P., et al. Appendix A. CD molecules. Middleton's allergy principles and practice 2014, 1663-1687. Elsevier Sanders, Philadelphia. 8th edition. N.F. Adkinson, B.S. Bochner, W.W. Busse (Eds.).
13. Tachimoto H., Bochner B.S. The surface phenotype of human eosinophils. Chem Immunol 2000, 76:45-62.
14. Bochner B.S. Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol 2004, 113:3-9.
15. Hamann J., Koning N., Pouwels W., et al. EMR1, the human homolog of F4/80, is an eosinophil-specific receptor. Eur J Immunol 2007, 37:2797-2802.
16. Legrand F., Tomasevic N., Simakova O., et al. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders. J Allergy Clin Immunol 2014, 133:1439-1447.
17. Migita M., Yamaguchi N., Mita S., et al. Characterization of the human IL-5 receptors on eosinophils. Cell Immunol 1991, 133:484-497.
18. Heath H., Qin S.X., Rao P., et al. Chemokine receptor usage by human eosinophils - The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997, 99:178-184.
19. Kikly K.K., Bochner B.S., Freeman S., et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells and basophils. J Allergy Clin Immunol 2000, 105:1093-1100.
20. Bochner B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 2009, 39:317-324.
21. Kiwamoto T., Kawasaki N., Paulson J.C., et al. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012, 135:327-336.
22. Nutku E., Aizawa H., Hudson S.A., et al. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003, 101:5014-5020.
23. Matsumoto K., Schleimer R.P., Saito H., et al. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995, 86:1437-1443.
24. Shen Z., Malter J.S. Determinants of eosinophil survival and apoptotic cell death. Apoptosis 2015, 10.1007/s10495-014-1072-2.
25. Bender I.K., Cao Y., Lu N.Z. Determinants of the heightened activity of glucocorticoid receptor translational isoforms. Mol Endocrinol 2013, 27:1577-1587.
26. Oakley R.H., Cidlowski J.A. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 2013, 132:1033-1044.
27. Pujols L., Mullol J., Roca-Ferrer J., et al. Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. Am J Physiol Cell Physiol 2002, 283:C1324-C1331.
28. Hsu J., Cao Y., Bender I.K., et al. Glucocorticoid receptor translational isoforms contribute to distinct glucocorticoid responses of neutrophils and eosinophils. J Allergy Clin Immunol 2012, 129:AB62. [abstract].
29. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325.
30. Prin L., Lefebvre P., Gruart V., et al. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. Clin Exp Immunol 1989, 78:383-389.
31. Gundel R.H., Letts L.G., Gleich G.J. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991, 87:1470-1473.
32. Uchida D.A., Ackerman S.J., Coyle A.J., et al. The effect of human eosinophil granule major basic protein on airway responsiveness in the rat in vivo. Am Rev Respir Dis 1993, 147:982-988.
33. Lefort J., Nahori M.A., Ruffie C., et al. In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest 1996, 97:1117-1121.
34. Wenzel S.E. Eosinophils in asthma-closing the loop or opening the door?. N Engl J Med 2009, 360:1026-1028.
35. Bochner B.S., Gleich G.J. What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol 2010, 126:16-25.
36. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
37. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
38. Jain N., Cortes J., Quintas-Cardama A., et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 2009, 33:837-839.
39. Butterfield J.H., Gleich G.J. Response of six patients with idiopathic hypereosinophilic syndrome to interferon-α. J Allergy Clin Immunol 1994, 94:1318-1326.
40. Butterfield J.H. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am 2007, 27:493-518.
41. Kern E., Hirano I. Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs 2013, 18:353-364.
42. Ghosh S., Goldin E., Gordon F.H., et al. Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
43. Miller D.H., Khan O.A., Sheremata W.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
44. Fedyk E.R., Wyant T., Yang L.L., et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012, 18:2107-2119.
45. Soler D., Chapman T., Yang L.L., et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009, 330:864-875.
46. Verstovsek S., Tefferi A., Kantarjian H., et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009, 15:368-373.
47. Kolbeck R., Kozhich A., Koike M., et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010, 125:1344-1353.e2.
48. Busse W.W., Katial R., Gossage D., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010, 125:1237-1244.
49. Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
50. Pavord I.D., Korn S., Howarth P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
51. Ortega H.G., Liu M.C., Pavord I.D., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014, 371:1198-1207.
52. Liu Y., Zhang S., Li D.W., et al. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One 2013, 8:e59872.
53. Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
54. Bel E.H., Wenzel S.E., Thompson P.J., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014, 371:1189-1197.
55. Gevaert P., Van Bruaene N., Cattaert T., et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011, 128:989-995.
56. Garrett J.K., Jameson S.C., Thomson B., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004, 113:115-119.
57. Rothenberg M.E., Klion A.D., Roufosse F.E., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
58. Roufosse F., de Lavareille A., Schandene L., et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:828-835.
59. Plotz S.G., Simon H.U., Darsow U., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003, 349:2334-2339.
60. Flood-Page P., Menzies-Gow A., Phipps S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029-1036.
61. Conus S., Straumann A., Bettler E., et al. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis. J Allergy Clin Immunol 2010, 126:175-177.
62. Kim S., Marigowda G., Oren E., et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343.
63. Kahn J.E., Grandpeix-Guyodo C., Marroun I., et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:267-270.
64. Herrmann K., Gross W.L., Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2012, 30:S62-S65.
65. Stein M.L., Collins M.H., Villanueva J.M., et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118:1312-1319.
66. Straumann A., Conus S., Grzonka P., et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010, 59:21-30.
67. Castro M., Mathur S., Hargreave F., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:1125-1132.
68. Castro M., Wenzel S.E., Bleecker E.R., et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014, 2:879-890.
69. Castro M., Zangrilli J., Wechsler M.E., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015, 3:355-366.
70. Brightling C.E., Bleecker E.R., Panettieri R.A., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014, 2:891-901.
71. Nowak R.M., Parker J.M., Silverman R.A., et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 2015, 33:14-20.
72. Spergel J.M., Rothenberg M.E., Collins M.H., et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012, 129:456-463. 463.e1-3.
73. Laviolette M., Gossage D.L., Gauvreau G., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013, 132:1086-1096.e5.
74. Fulkerson P.C., Fischetti C.A., McBride M.L., et al. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A 2006, 103:16418-16423.
75. Humbles A.A., Lu B., Friend D.S., et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A 2002, 99:1479-1484.
76. Ma W., Bryce P.J., Humbles A.A., et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002, 109:621-628.
77. Wise E.L., Duchesnes C., da Fonseca P.C., et al. Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem 2007, 282:27935-27943.
78. Neighbour H., Boulet L.P., Lemiere C., et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2014, 44:508-516.
79. Barnes N., Pavord I., Chuchalin A., et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012, 42:38-48.
80. Singh D., Cadden P., Hunter M., et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J 2013, 41:46-52.
81. Straumann A., Hoesli S., Bussmann C., et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013, 68:375-385.
82. Vermeire S., O'Byrne S., Keir M., et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014, 384:309-318.
83. Cudkowicz M.E., van den Berg L.H., Shefner J.M., et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013, 12:1059-1067.
84. Zimmermann N., Hershey G.K., Foster P.S., et al. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003, 111:227-242.
85. Steinke J.W., Rosenwasser L.J., Borish L. Cytokines in allergic inflammation. Middleton's allergy principles and practice 2014, 65-82. Elsevier Sanders, Philadelphia. 8th edition. N.F. Adkinson, B.S. Bochner, W.W. Busse (Eds.).
86. Luttmann W., Knoechel B., Foerster M., et al. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol 1996, 157:1678-1683.
87. Corren J., Lemanske R.F., Hanania N.A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
88. Noonan M., Korenblat P., Mosesova S., et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013, 132:567-574.
89. Scheerens H., Arron J.R., Zheng Y., et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014, 44:38-46.
90. Reinisch W., Panes J., Khurana S., et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 2015, 64:894-900.
91. Danese S., Rudzinski J., Brandt W., et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015, 64(2):243-249.
92. Murray L.A., Zhang H., Oak S.R., et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol 2014, 50:985-994.
93. Piper E., Brightling C., Niven R., et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013, 41:330-338.
94. Hodsman P., Ashman C., Cahn A., et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol 2013, 75:118-128.
95. De Boever E.H., Ashman C., Cahn A.P., et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014, 133:989-996.
96. Corren J., Busse W., Meltzer E.O., et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am J Respir Crit Care Med 2010, 181:788-796.
97. Wenzel S., Ford L., Pearlman D., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
98. Beck L.A., Thaci D., Hamilton J.D., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014, 371:130-139.
99. Gauvreau G.M., O'Byrne P.M., Boulet L.P., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014, 370:2102-2110.
100. Gauvreau G.M., Boulet L.P., Leigh R., et al. A non-steroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med 2014, 10.1164/rccm.201404-0623OC.
101. Akdis C.A. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 2012, 18:736-749.
102. Oh C.K., Leigh R., McLaurin K.K., et al. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 2013, 14:93.
103. Ding C., Li J., Zhang X. Bertilimumab Cambridge Antibody Technology Group. Curr Opin Investig Drugs 2004, 5:1213-1218.
104. Blanchard C., Wang N., Stringer K.F., et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006, 116:536-547.
105. Caldwell J.M., Collins M.H., Stucke E.M., et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol 2014, 134:1114-1124.
106. Available at: . ReleaseID-5821931. Accessed May 30, 2015. http://ir.kalobios.com.
107. Groopman J.E., Mitsuyasu R.T., DeLeo M.J., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987, 317:593-598.
108. Bochner B.S., Friedman B., Krishnaswami G., et al. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1991, 88:629-636.
109. Divekar R.D., Samant S., Rank M.A., et al. Immunological profiling in chronic rhinosinusitis with nasal polyps reveals distinct VEGF and GMCSF signatures during symptomatic exacerbations. Clin Exp Allergy 2015, 45(4):767-778.
110. Gauvreau G.M., Boulet L.P., Cockcroft D.W., et al. Antisense therapy against CCR3 and the common β chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958.
111. Gauvreau G.M., Pageau R., Seguin R., et al. Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy 2011, 66:1242-1248.
112. Imaoka H., Campbell H., Babirad I., et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin Exp Allergy 2011, 41:1740-1746.
113. Roufosse F.E., Kahn J.E., Gleich G.J., et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013, 131:461-467.
114. Haldar P., Brightling C.E., Singapuri A., et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 2014, 133:921-923.
115. Kim Y.J., Prussin C., Martin B., et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004, 114:1449-1455.
116. Gleich G.J., Klion A.D., Lee J.J., et al. The consequences of not having eosinophils. Allergy 2013, 68:829-835.
117. Klion A.D., Robyn J., Maric I., et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007, 110:3552-3556.
118. Furuta G.T., Kagalwalla A.F., Lee J.J., et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut 2013, 62:1395-1405.
119. Lukawska J.J., Livieratos L., Sawyer B.M., et al. Real-time differential tracking of human neutrophil and eosinophil migration in vivo. J Allergy Clin Immunol 2014, 133:233-239.e1.
120. Farahi N., Loutsios C., Peters A.M., et al. Use of technetium-99m-labeled eosinophils to detect active eosinophilic inflammation in humans. Am J Respir Crit Care Med 2013, 188:880-882.
121. Wen T., Besse J.A., Mingler M.K., et al. Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo. Proc Natl Acad Sci U S A 2013, 110:6067-6072.
122. Loutsios C., Farahi N., Porter L., et al. Biomarkers of eosinophilic inflammation in asthma. Expert Rev Respir Med 2014, 8:143-150.
123. Na H.J., Hamilton R.G., Klion A.D., et al. Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8. J Immunol Methods 2012, 383:39-46.
124. Mawhorter S.D., Stephany D.A., Ottesen E.A., et al. Identification of surface molecules associated with physiologic activation of eosinophils - application of whole-blood flow cytometry to eosinophils. J Immunol 1996, 156:4851-4858.
125. Bochner B.S. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000, 106:S292-S302.
126. Jia G., Erickson R.W., Choy D.F., et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012, 130:647-654.
127. Nair P., Kraft M. Serum periostin as a marker of T(H)2-dependent eosinophilic airway inflammation. J Allergy Clin Immunol 2012, 130:655-656.
128. Hijnen D., De Bruin-Weller M., Oosting B., et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004, 113:334-340.
129. Wilson T.M., Maric I., Shukla J., et al. IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol 2011, 128:1086-1092.
130. Nair P., Ochkur S.I., Protheroe C., et al. Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy 2013, 68:1177-1184.
131. Butterfield J.H., Leiferman K.M., Abrams J., et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992, 79:688-692.
132. Simon H.U., Plotz S.G., Dummer R., et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999, 341:1112-1120.
133. Gevaert P., Lang-Loidolt D., Lackner A., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006, 118:1133-1141.